SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis.

Bruce Anthony Campbell CreeRachel MadduxAmit Bar-OrHans-Peter HartungAmandeep KaurElizabeth A BrownYicong LiYanhua HuJames K SheffieldDiego SilvaSarah Harris

Published in: Annals of clinical and translational neurology (2023)

Most ozanimod-treated participants with RMS mounted a serologic response to SARS-CoV-2 vaccination and infection, regardless of participant characteristics or ALC levels. In this analysis, all COVID-19-related AEs post-full vaccination in participants taking ozanimod were nonserious and not severe.

Keyphrases

sars cov
multiple sclerosis
respiratory syndrome coronavirus
coronavirus disease
white matter
newly diagnosed
disease activity
rheumatoid arthritis